Laboratory evaluation of the patient with liver disease

European Review for Medical and Pharmacological Sciences

Volumn 8, Issue 1, 2004, Pages 3-9

  Astegiano, M ^a   Sapone, N ^a   Demarchi, B ^a   Rossetti, S ^a   Bonardi, R ^a   Rizzetto, M ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

AST; Function test; Liver

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILE ACID; BILIRUBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; CAFFEINE; FIBRINOGEN; GALACTOSE; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; LIDOCAINE; PHENAZONE; PROTHROMBIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE ACID BLOOD LEVEL; BILE DUCT OBSTRUCTION; BILIRUBIN BLOOD LEVEL; BIOCHEMISTRY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG METABOLISM; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS; HUMAN; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER BIOPSY; LIVER DISEASE; LIVER FUNCTION; LIVER FUNCTION TEST; PATIENT MONITORING; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SYMPTOMATOLOGY;

HUMANS; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; PHARMACEUTICAL PREPARATIONS;

EID: 2442686506     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Pratt DS, Kaplan MM. Evaluation of abnormal liver function: principles and practice. J Gastroenterol Hepatol 1990; 5: 468.
2. Johnson RD, O'Connor ML, Kerr RM. Extreme serum elevations of aspartate aminotransferase. Am J Gastroenterol 1995; 90: 1244.
3. Hay JE, Czaja AJ, Rakela J, et al. The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology 1989; 9: 193.
4. Goddard CJ, Warnes TW. Raised liver enzymes in asymptomatic patients: investigation and outcome. Dig Dis 1992; 10: 218.
5. Bardella MT, Vecchi M, Conte D, et al. Chronic unexplained hypertransaminasemia may be caused by occult celiac disease. Hepatology 1999; 29: 654.
6. Bonamico M, Pitzalis G, Culasso F. Hepatic damage during celiac disease in childhood. Minerva Pediatr 1986; 38: 959.
7. Berasain C, Betés M, Panizo A, et al. Pathological and virological findings in patients with persistent hypertransaminasemia of unknown etiology. Gut 2000; 47: 429.
8. Cassidy WM, Reynolds TB. Serum lactic dehydrogenase in the differential diagnosis of acute hepatocellular injury. J Clin Gastroenterol 1994;19: 118.
9. Dickson ER, Grambsch PM, Fleming TR, et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10: 1.
10. O'Grady JG, Alexander GJM, Hayllar KM, et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97: 439.
11. Jalan R, Hayes PC. Review article: quantitative tests of liver function. Aliment Pharmacol Ther 1995; 9: 263.
12. Weitz IC, Liebman HA. Des-γ-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 1993; 18: 990.
13. Grant A, Neuberger J. Giudelines on the use of liver biopsy in clinical practice. Gut 1999; 45 (Suppl IV): IV 1.
14. Halfon P, Imbert-Bismut F, Messous D, et al. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 2002; 1 (1): 3.